Inclisiran
Inclisiran is an experimental drug for the treatment of patients with atherosclerotic cardiovascular disease, ASCVD risk equivalents and heterozygous familial hypercholesterolemia. It is a small interfering RNA that inhibits translation of the protein PCSK9.
It is being developed by The Medicines Company which licensed the rights to inclisiran from Alnylam Pharmaceuticals.
In 2019 The Medicines Company announced positive results from pivotal phase III study. The company anticipates regulatory submissions in the U.S. in the fourth quarter of 2019, and in Europe in the first quarter of 2020. The Medicines Company is being acquired by Novartis.
